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Abstract
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This retrospective cohort study was designed to determine the yield of genetic tests
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the inclusion criteria. Diagnostic yields were 32% for karyotype, 19% for microarray,

Department of Pathology and Laboratory
Medicine, Cytogenetics and Molecular
Genetics Laboratories, Children's Mercy
Hospital, Kansas City, Missouri, USA
4

in hypotonic infants and develop a diagnostic algorithm. Out of 496 patients identified by International Classification of Diseases (ICD) 9/10 coding, 324 patients met
30% for targeted genetic tests, 38% for gene panels, and 31% for exome sequencing.
In addition, we considered the diagnostic contribution of ancillary tests, including
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neuroimaging, metabolic tests, and so forth. The combination of microarray and
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exome sequencing gave the highest diagnostic yield. None of the other tests added
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significant value in arriving at a diagnosis. Based on these results we propose that the
vast majority of infants with congenital hypotonia should start with a microarray and
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syndromic features in whom karyotyping or targeted testing may be more
appropriate.
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proceed with exome sequencing, with the notable exception of infants with clearly

genetic testing, hypotonia, syndrome, whole exome sequencing

I N T RO DU CT I O N

should be used first line, whereas specific metabolic testing, nerve
conduction study/Electromyography and muscle biopsy should be

Hypotonia is defined as decreased resistance to passive movement

reserved as second line testing modalities.5

and is a common abnormal clinical finding in infants, especially during

With the advent of Next Generation Sequencing (NGS) testing

the neonatal period.1 Studies have estimated the incidence of congen-

has markedly improved over the last decade and this has had a unique

ital hypotonia in term infants to be 0.8/1000 births by extrapolating

impact on the evaluation of hypotonic infants. Yet, there is a lack of

the incidence of the commonest cause, hypoxic ischemic encephalop-

information regarding the diagnostic yield of different types of genetic

athy, to the general population.2

tests in hypotonic infants. This lack of information has resulted in a

Hypotonia can occur in association with multiple genetic and/or

diagnostic approach largely based on expert opinion. Wang et al

acquired etiologies. Several algorithms have been suggested to

reported 186 neonates with hypotonia out of which 89 underwent

3–5

Laugel et al. assessed the yield

targeted NGS. They uncovered a diagnosis in 20 (22.5%) patients,6

of the different types of testing in 144 neonates with hypotonia. They

including six novel mutations. We conducted a retrospective review

suggested that neuroimaging, karyotype, and molecular testing

of 324 consecutive infants with a diagnosis of congenital hypotonia

help streamline this evaluation.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
© 2021 The Authors. Clinical Genetics published by John Wiley & Sons Ltd.
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to report the diagnostic yield of genetic testing and propose a diag-

0.4353, 0.8252]). There was no significant association between the

nostic algorithm in this patient population.

diagnostic yield of microarray and targeted genetic tests (Fisher's
exact test, p-value = 0.012) or that of microarray and gene panels (p
value = 1.00). Of the 41 diagnoses obtained by targeted genetic test-

2
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MATERIALS AND METHODS

ing, nine (22%) had PWS, seven (17%) had SMA, three (7%) had myotonic dystrophy, one (2%) had AS, and 21 (54%) had another

This is a retrospective cohort study of infants aged 0–12 months with

recognizable syndrome. Two patients who had a nondiagnostic or

a diagnosis of hypotonia (ICD 10 code P94.2, ICD 9 codes 781.3 and

non-informative gene panel but a diagnostic or positive microarray,

781.99) seen at a tertiary care hospital (Children's Mercy Hospital,

were found to have chromosomal microdeletions (Table S2). Five

Kansas City, MO) between January 1, 2014 and January 1, 2019. The

patients, who had a nondiagnostic WES but diagnostic microarray,

study protocol was approved by the hospital's institutional review

were found to have chromosomal deletion, duplication, or unbalanced

board. A waiver of parental permission/child assent was granted since

translocation (Table S3).
The most common clinical features in this patient population

this was a data collection study only. Data was obtained via an electronic medical record query.

were developmental delay (82%), followed by gastrointestinal

Patients who did not have genetic testing were excluded. Our

disorders (48%), dysmorphism (33%), respiratory disorders (26%), con-

primary aim was to determine and compare diagnostic yield of

genital heart disease (24%), and epilepsy (20%). In most of the cases

genetic testing (karyotype, microarray, targeted genetic testing for

developmental delay was an a posteriori observation gathered from

specific conditions, gene panels, whole exome [WES], or whole

chart review. Of the 29 patients with hypotonia whose sole other clin-

genome sequencing [WGS]). A secondary aim was to test if clinical

ical feature was developmental delay, eight (28%) were eventually

variables (demographics, type of hypotonia [axial, appendicular, or

diagnosed through genetic testing. We attempted to identify symp-

diffuse], associated symptoms, neuroimaging results, and metabolic

toms that might increase the yield of genetic tests. Karyotype was the

testing results) increased the yield of testing and if the results prompted

only test, when comparing diagnostic versus nondiagnostic results

a clinical intervention (medication, therapy, or counseling).

that flagged clinical symptoms as candidate variables. A stepwise

Targeted genetic testing consisted of single gene testing with

logistic regression model applied to 148 individuals who underwent

reflex to deletion/duplication analysis for unique syndromes based on

karyotype revealed that dysmorphism increases the odds of obtaining

clinical suspicion, methylation and copy number analysis for Prader–

a diagnostic karyotype by 15-fold (95% OR; CI: 6.1, 36; p-

Willi (PWS) or Angelman syndrome (AS), DMPK gene expansion for

value = <0.0001). The most common type of hypotonia noted in

myotonic dystrophy, FMR1 triplet repeats for Fragile X syndrome, and

212 out of 324 patients (65%) was diffuse hypotonia, that is, axial and

so forth.

appendicular low tone on physical exam. There was a significant association between the presence of diffuse hypotonia and a diagnostic
karyotype result (p-value = < 0.001, Table S4).

3
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RESULTS

Two hundred fifty-five patients had a brain magnetic resonance
imaging (MRI), of those 126 (49%) were abnormal. No MRI abnormality

We identified 496 patients out of which 172 were excluded due to

was found to associate with an increased yield of any genetic test

absence of genetic testing and 324 met inclusion criteria (Figure 1).

(Fisher's exact p-value = 0.9558, Table S5). We also looked at the yield

Among them, 171 (52.77%) were male and 153 (47.22%) were female.

of metabolic testing in this patient population. Of the 209 patients who

Mean age at presentation was 5.17 months (SD ± 4.01 months) with a

underwent some combination of metabolic testing (serum amino acids,

median age of 5.33 months (IQR 0.87, 8.92). Overall, 176 out of

acylcarnitine profile, urine organic acids, very long chain fatty acids, etc.)

324 (54%) patients achieved a diagnosis by one or more of the genetic

seven (3%) patients were diagnostic (Table S6). Of those, four were con-

testing methods. The diagnostic yield of different genetic tests is

firmed by NGS. Among the study population we identified novel patho-

detailed in Figure 1. Note that some patients underwent more than

genic or likely pathogenic variants in 18 patients (6%) out of which

one genetic test and therefore the sum of percentages of yield

13 remain unpublished (Table 1). Finally, we evaluated for any interven-

exceeds 100% (Table S1). Of 176 patients with a diagnosis, 20% were

tion following the genetic diagnoses. Of 176 patients with a molecular

found to have a chromosomal abnormality, 26% were found to have a

diagnosis, 172 (98%) received some combination of physical, occupa-

copy number change, 45% were found to have single nucleotide vari-

tional, and/or speech therapy, 161 patients (91%) received genetic

ants, and 9% were diagnosed through one of the targeted genetic

counseling, and 10 patients (6%) received a disease altering drug includ-

testing methods, which included methylation studies, trinucleotide

ing two SMA patients who received avxs-101 gene therapy (Table S7).

repeats, and so forth (Figure 1). Of the 48 patients with diagnostic
karyotypes, 35 (73%) had trisomies. One patient had a negative microarray but a diagnostic karyotype that showed a mosaic duplication of

4
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DI SCU SSION

the distal long arm of Chromosome 17. Using Cohen's kappa of
McNemar's test, we found substantial concordance between the diag-

The list of conditions that cause congenital hypotonia is extensive and the

nostic yield of karyotype and microarray (kappa = 0.6303 [95% CI

approach to the diagnostic workup is complex. We attempted to clarify this
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F I G U R E 1 Schematic
representation of diagnostic yield
of genetic testing in study
population

conundrum by proposing a sequential diagnostic approach (Figure 2).

Targeted genetic tests are cheaper ($356–$1800) and have a faster

We observed a relatively high diagnostic yield of karyotype likely

turnaround time (7–14 days) than microarrays ($3650, 14 days) or WES

due to majority of these patients having trisomies that are easily rec-

($5610, 27 days). We recommend pursuing these tests in recognizable

ognizable clinically. Eighty-three percent (29/35) of the patients with

clinical syndromes (PWS, AS, SMA, myotonic dystrophy, etc.). However,

clinically obvious dysmorphic features had a karyotype but no micro-

out of 176 patients with a diagnosis, 26% had a CNV picked up on

array done. Had all of these patients been tested by microarray; the

microarray and seven patients had CNVs that were missed on gene

yield of the microarray would have been much higher. The microar-

panels or WES (Tables S2 and S3). At our institution, a microarray is sig-

ray was used almost exclusively for patients who did not have an

nificantly cheaper and has a faster turnaround time than WES ($3650

obvious recognizable syndrome. This may account for the slightly

vs. $5610, 14 vs. 27 days). We recommend starting with a microarray

lower yield of the microarrays (19%) in our study. Given that a micro-

for all infants with congenital hypotonia who do not have a clinically rec-

array will pick up vast majority of copy number variations (CNV), we

ognizable syndrome. This is in line with recommendation for first tier

argue that it is no longer necessary to obtain a karyotype, except for

testing made by American College of Medical Genetics and Genomics

patients with easily recognizable trisomies such as Down syndrome.

(ACMG) targeted toward congenital anomalies and intellectual disability.7
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deficit, and so forth

F I G U R E 2 Infants with hypotonia require a step-wise approach toward diagnosis. In the absence of clinical features associated with a specific
genetic disease, the highest diagnostic yield can be achieved by microarray with reflex to whole exome sequencing

It is worth noting that incorporation of deletion/duplication algorithms

unnecessary cost and time to the diagnostic process. We recommend

into WES analysis is becoming more broadly adopted and may reduce

proceeding with WES when a microarray is nondiagnostic.

the utility of microarrays in the future.8

In most studies, the diagnostic yield of WES (40%) is only slightly

Yang et al. reported a diagnostic rate of 25% using WES in patients

lower than that of WGS (42%).10 At this time, we do not believe that

with suspected genetic disease, with a higher yield (36%) in children with

there is a strong rationale for obtaining genome sequencing over

neurologic symptoms.9 We observed a diagnostic yield of 31% in

exome sequencing except for a few extraordinary cases where time is

patients who underwent WES. Furthermore, 18 of the disease-causing

of the essence and an all-encompassing diagnostic test will allow for

variants were novel variants at the time of diagnosis that would have

life altering clinical decisions.11

been missed with other genetic testing methods. In our cohort, seven of

Often when hypotonic infants present with developmental

the patients who underwent gene panels required WES. This adds

delay as their only other symptom they are labeled as “benign”
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and diagnostic evaluation is withheld.12 We identified 29 such

Janelle R. Noel-MacDonnell

patients, of which eight (28%) were eventually diagnosed with a

6056

genetic disease. Withholding evaluation in these patients may lead

Jean-Baptiste LePichon
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to a delay in diagnosis, potential therapeutic interventions, and
genetic counseling.
A logistic regression analysis showed that dysmorphism increases
the odds of a diagnostic karyotype, likely due to large number of
patients with trisomies. This is in agreement with other studies that
have reported high yields for karyotype testing when applied to
patients with dysmorphic features.13
We identified a diagnostic yield of only 3% by metabolic tests,
which indicate that pursuing metabolic testing in patients with hypotonia may not be necessary unless a metabolic disorder is strongly
suspected and/or has an actionable outcome.
Limitations of this study include the retrospective nature of the
study and absence of controls inherent to retrospective studies. The
variability in provider decision making may impart a bias to the results.
In addition, this is a single-center study and therefore the specific
arguments regarding cost and turnaround time may vary. Nevertheless, this retrospective review of 324 hypotonic infants shows that a
diagnosis will be arrived at in 54% patients via genetic testing and that
for many of these patients the results will be actionable. With the
exception of infants with an obviously recognizable syndrome,
the best approach is to start with a microarray and proceed with
exome sequencing if the microarray is nondiagnostic. Gene panels are
probably not cost effective when one considers the number of
patients who will need to proceed to WES. It is our hope that this
approach to the infant with hypotonia will simplify the diagnostic
conundrum these patients have long represented for clinicians.
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